Phaseline

Companies › MED Institute

MED Institute: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
Umbilical cord-derived mesenchymal stem cells
–Phase 2Duchenne Muscular DystrophyOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06579352Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)Phase 2Duchenne Muscular DystrophyNeurologyOct 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nippon Shinyaku NeuroPace Alasht Pharmed Sound Wave Innovation Elpida Therapeutics SPC

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.